Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 7 , ISSUE 2 ( May-August, 2015 ) > List of Articles

REVIEW ARTICLE

Medical Management of Uterine Leiomyoma: A Comprehensive Review

Kiranmai Devineni

Citation Information : Devineni K. Medical Management of Uterine Leiomyoma: A Comprehensive Review. J South Asian Feder Obs Gynae 2015; 7 (2):71-76.

DOI: 10.5005/jp-journals-10006-1327

Published Online: 01-12-2016

Copyright Statement:  Copyright © 2015; The Author(s).


Abstract

PDF Share
  1. editor. Dewhurst's Textbook of Obstetrics and Gynaecology for Postgraduates. 4th ed. London: Black well, 1986:726-733.
  2. In: Thompson JD, Rock JA, editors. TeLinde's Operative Gynaecology. 7th ed. Philadelphia: Lippincott, 1992.
  3. Uterine leiomyomas: etiology, symptomatology, and management. Fertil Steril 1981;36: 433-445.
  4. Abnormal uterine bleeding associated with iron-deficiency anaemia: etiology and role of hysteroscopy. J Reprod Med 1993;38:502-504.
  5. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue. Obstet Gynecol 1980;55:20-24.
  6. Comparison of cellular levels of steroid receptors in uterine leiomyomas and myometrium. Acta Gynaecol Scand 1985;64:307-309.
  7. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women. Clin Endocrinol 1994;40(4): 537-544.
  8. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynaecol 1989;96:200-206.
  9. Goserelin (Zoladex) in the treatment of fibroids. Br J Obstet Gynaecol 1992;99(Suppl 7):27-30.
  10. Ulipristal Acetate versus Placebo for fibroid treatment before surgery. N Engl J Med 2012 Feb 2;366(5):409-420.
  11. Efficacy of preoperative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG: Int J Obstet Gynaecol 2002;109:1097-1108.
  12. J Clin Endocrinol Metab 2001;86(11): 5405-5411.
  13. Effects of progesterone on growth factor expression in human uterine leiomyoma Steroids 2003;68(10-13):817-824.
  14. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988;49:404
  15. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217
  16. Fertil A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata 1998;70(3):432
  17. Overview of treatment of uterine leiomyomas (fibroids). In: Barbieri RL, Falk SJ, editors. Available at: http://www.uptodate.com .
  18. Surgery versus medical therapy for heavy menstrual bleeding. Farquhar Cochrane Database Syst Rev 2006 Apr 19;(2):CD003855.
  19. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003; 79(5):1194
  20. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids]. Ginekol Pol 2000;71(9):1221
  21. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 2007;75(3):193
  22. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 10; 82(1):41
  23. New concepts in the treatment of uterine leiomyomas. Obstet Gynecol 1998;92:624-627.
  24. Levonoegestrel releasing intrauterine system in the treatment of heavy menstrual bleeding. Curr O Pin Obstet Gynecol 2004;16(6):487-490.
  25. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. Obstet Gynaecol 2004;24(7):798
  26. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004;159(2):113
  27. Options for medical treatment of myomas. Obstet Gynecol Clin N Am 2006;33:97-113.
  28. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 1992;166:746-751.
  29. Two-step gonadotropin releasing hormone agonist treatment of uterine leiomyomas standard-dose therapy followed by reduced-dose therapy. Am J Obstet Gynecol 1996;175:1208-1216.
  30. Efficacy of preoperative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG 2002;109:1097-1108.
  31. Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol 1995;86:386-388.
  32. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyoma in Japanese women. Fertil Steril 1992;58:66-71.
  33. Ultrasonographic evaluation of the change in uterine fibroids induced by treatment with a GnRH analog. Taiwan J Obstet Gynecol 2006;45:124-128.
  34. The histopathology of uterine leiomyomas following treatment with gonadotropin releasing hormone analogues. Hum Pathol 1993;24:1073-1077.
  35. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endocrinol Metab 1998;83: 1253-1255.
  36. Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol 1996;68:169-173.
  37. Enhanced deoxyribonucleic acid damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist. Am J Obstet Gynecol 1997;177:417-424.
  38. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol 1995;86:65-71.
  39. Rationale of myomectomy for perimenopausal women. Maturitas 2007;58:406-407.
  40. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil Steril 1992;58:413-415.
  41. Impact of different GnRH analogs in benign gynecological disorders related to their chemical structure, delivery systems and dose. Gynecol Endocrinol 1994;8:215-222.
  42. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolideacetate. Fertil Steril 1990;53:1018-1023.
  43. Relationship between hormone receptor concentration and tumor shrinkage in uterine myoma after treatment with a GnRHa. Zhonghua Yi Xue Za Zhi (Taipei) 1999;62: 294-299.
  44. Usefulness of Doppler ultrasound in predicting the effect of gonadotropin-releasing hormone agonist (GnRHa) on myoma uteri. Nippon Sanka Fujinka Gakkai Zasshi 1995;47:1255-1260.
  45. Ultrasonography prediction of the efficacy of GnRH agonist therapy before laparoscopy myomectomy. J Am Assoc Gynecol Laparosc 1998;5:361-366.
  46. Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment. Fertil Steril 1997;68:632-636.
  47. Differential efficacy of gonadotropin-releasing hormone (GnRH) agonist treatment on pedunculated and degenerated myomas: a retrospective study of 630 women. J Obstet Gynaecol 2000;20:504-506.
  48. Standard and low-dose hormone therapy for postmenopausal women—focus on the breast. Taiwan J Obstet Gynecol 2007; 46:127-134.
  49. Effects of tibolone on the breast of postmenopausal women. Taiwan J Obstet Gynecol 2007;50:121-126.
  50. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone releasing hormone agonist implant: a pilot study. Hum Reprod 1991;6:500-505.
  51. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study. Fertil Steril 1994;62:938-942.
  52. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Hum Reprod 2004;19: 1308-1313.
  53. Long term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass and lipid profiles. Fertil Steril. 1999;72:889-895.
  54. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata: a pilot study. Eur J Obstet Gynecol Reprod Biol 2001;96(2):183-186.
  55. Raloxifene administration in premenopausall women with uterine leiomyomas in postmenopausal women. Fertil Steril 2001;76(1):38-43.
  56. Russo T Orio Jr. Fetal Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas : a prospective, randomized, single blind placebo controlled clinical trial Hum Reprod 2002;17(12):3213-3219.
  57. Systematic review of mifeprestone for the treatment of uterine leiomyomata Obstet Gynecol 2004;103(6):1331-1336.
  58. Treatment of uterine leiomyomas with the novel SPRM J. Soc Gynecolol Investig 2003;10(2 suppl):Abstract 301A.
  59. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92:3582-3589.
  60. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced anti glucocorticoid activity: in vitro comparison to mifepristone and CDB-2914 Mol Cell Endocrinol 2002;188:111-123.
  61. Ulipristal Acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012 Feb 2;366-365.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.